Derek J. Maetzold Sells 2,869 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating) insider Derek J. Maetzold sold 2,869 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $20.84, for a total value of $59,789.96. Following the sale, the insider now owns 289,520 shares in the company, valued at $6,033,596.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Stock Down 0.0 %

Shares of CSTL stock traded down $0.01 on Thursday, hitting $21.07. 132,886 shares of the stock were exchanged, compared to its average volume of 240,834. Castle Biosciences, Inc. has a one year low of $15.58 and a one year high of $48.40. The firm’s 50 day moving average is $23.87 and its two-hundred day moving average is $24.53.

Analysts Set New Price Targets

CSTL has been the topic of several analyst reports. Robert W. Baird reduced their target price on Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. SVB Leerink upped their target price on Castle Biosciences from $45.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 9th. Finally, BTIG Research increased their price target on Castle Biosciences to $47.00 in a research report on Monday, August 15th. Five analysts have rated the stock with a buy rating, According to, the stock has an average rating of “Buy” and an average price target of $57.86.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CSTL. Park Avenue Securities LLC bought a new stake in shares of Castle Biosciences during the first quarter valued at approximately $291,000. Envestnet Asset Management Inc. increased its position in Castle Biosciences by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 38,776 shares of the company’s stock valued at $1,739,000 after acquiring an additional 5,337 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Castle Biosciences during the first quarter valued at $206,000. Pictet & Cie Europe SA grew its holdings in Castle Biosciences by 10.7% during the first quarter. Pictet & Cie Europe SA now owns 10,724 shares of the company’s stock valued at $481,000 after purchasing an additional 1,035 shares during the period. Finally, Isthmus Partners LLC boosted its stake in shares of Castle Biosciences by 6.4% in the first quarter. Isthmus Partners LLC now owns 40,223 shares of the company’s stock worth $1,804,000 after acquiring an additional 2,414 shares during the period. Hedge funds and other institutional investors own 86.08% of the company’s stock.

Castle Biosciences Company Profile

(Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Read More

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with's FREE daily email newsletter.